Other

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Sciclone Pharmaceuticals, Inc.

Andrey S Simbirtsev

Alexander A Kolobov

Edward G Lakatta

Sergey A Ketlinsky

Nikolai Kolodkin

Vladimir M Shpen

Sergey V Kulikov

Alexander Kotov

Oleg A Kaurov

Alexei Bagrov

Alexander U Kotov

Alexandr A Kolobov

Natalia V Pigareva

Natal'ya V Zabolotnyh

Natalia M Kalinina

Olga V Fedorova

Tat'yana I Vinogradova

Alexey N Prusakov

Described herein are deposited hybridoma cell lines and the monoclonal antibodies produced by these hybridomas, and antigen binding fragments thereof. These monoclonal antibodies and antigen binding fragments specifically bind marinobufagenin. The disclosure also encompasses the use of these monoclonal antibodies or antigen binding fragments in a method for detecting the presence of marinobufagenin in a biological sample. Also provided are methods for the use of these monoclonal antibodies or antigen binding fragments as prophylactic, therapeutic, and diagnostic agents for the detection, inhibition and treatment of a cardiovascular disease, for example, essential hypertension, hypertension associated with preeclampsia, eclampsia, or renal failure, or myocardial fibrosis in a subject.

Anti-marinobufagenin antibodies and methods for their use

Tuberculosis in an animal is treated by administration of a therapeutically effective amount of an immunomodulator of formula A. In formula (A), n is 1 or 2, R is hydrogen, acyl, alkyl or a peptide fragment, and X is an aromatic or heterocyclic amino acid or a derivative. The animal may be a mammal such as a human 

Treatment of tuberculosis using immunomodulator compounds

Synthetic immunomodulatory molecules having a .gamma.-L-glutamyl-, a .gamma.-D-glutamyl, a .beta.-L-aspartyl, or a .beta.-D-aspartyl moiety at the amino terminus are provided as illustrated by Formula A. In Formula A, 'n' is 1 or 2, R is hydrogen, acyl or alkyl, and X is an aromatic or heterocyclic amino acid or its derivative. A particularly preferred embodiment is .gamma.-D-glutamyl-L-tryptophan, which has immunomodulatory activity.

.gamma.-glutamyl and .beta.-aspartyl containing immunomodulator

The new class of synthetic immunomodulatory molecules having a .gamma.-L-glutamyl- moiety at the amino terminus are provided as illustrated by Formula 1. ##STR1## In Formula 1, the Greek symbols designate the noted carbon atoms, R is hydrogen, acyl or alkyl, and X is an aromatic or heterocyclic amino acid or its derivative. Included as members of the new class (in addition to Bestim, .gamma.-L-glutamyl-L-tryptophan) are those compounds where R=hydrogen and X=L-tryptophan, such as .gamma.-L-glutamyl-N.sub.in -formyl-L-tryptophan, N-methyl-.gamma.-L-glutamyl-L-tryptophan, N-acetyl-.gamma.-L-glutamyl-L-tryptophan, and .gamma.-L-glutamyl-.beta.-thienyl-D-alanylamide. A preferred embodiment, termed 'BESTIM,' has the chemical structure of .gamma.-L-glutamyl-L-tryptophan.

.gamma.-L-glutamyl containing immunomodulator compounds and methods

Growing community of inventors

St.-Petersburg, Russia

Andrey S Simbirtsev